Having trouble accessing articles? Reset your cache.

Synosia, UCB deal

Synosia granted UCB exclusive, worldwide rights to Parkinson's disease candidate SYN-115, an oral adenosine A2A receptor (ADORA2A) inhibitor. UCB also

Read the full 209 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE